Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:50:40.394Z.
Calculation as of: 2026-10-06T12:50:40.394Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa76e0b4cf372acfd55719bf770982f56833f7348901d63cf8ce2fa77c35bda7
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$2.05B
PE Ratio
15.31
TTM Avg
29.48
3Y Avg
184.64
5Y Avg
184.64
Market Cap
$2.02B
PE Ratio
6.86
TTM Avg
15.39
3Y Avg
40.25
5Y Avg
40.25
Market Cap
$2.11B
PE Ratio
19.82
TTM Avg
21.19
3Y Avg
24.83
5Y Avg
28.15
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioCryst Pharmaceuticals, Inc. (BCRX) | $2.06B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.07B | N/A | 33.55 | 33.55 | 33.55 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.05B | 15.31 | 29.48 | 184.64 | 184.64 |
| Immunome, Inc. (IMNM)vs › | $2.02B | N/A | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 6.86 | 15.39 | 40.25 | 40.25 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 19.82 | 21.19 | 24.83 | 28.15 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | N/A | 34.42 | 34.42 | 34.42 |
| AxoGen, Inc. (AXGN)vs › | $2.00B | N/A | 1.02 | 1.02 | 39.76 |
| Azenta, Inc. (AZTA)vs › | $1.97B | N/A | 61.77 | 49.90 | 40.42 |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.96B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$8.10
Forward EPS (Est.)
$-2.29
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-05-06 | 7.37 |
| 2026-05-05 | 7.53 |
| 2026-05-04 | 7.67 |
| 2026-05-01 | 7.67 |
| 2026-04-30 | 7.64 |
| 2026-04-29 | 7.50 |
| 2026-04-28 | 7.39 |
| 2026-04-27 | 7.42 |
| 2026-04-24 | 7.46 |
| 2026-04-23 | 7.31 |
| 2026-04-22 | 7.52 |
| 2026-04-21 | 7.16 |
| 2026-04-20 | 7.67 |
| 2026-04-17 | 7.93 |
| 2026-04-16 | 7.94 |
| 2026-04-15 | 7.88 |
| 2026-04-14 | 8.07 |
| 2026-04-13 | 7.85 |
| 2026-04-10 | 7.98 |
| 2026-04-09 | 8.25 |
| 2026-04-08 | 8.16 |
| 2026-04-07 | 8.00 |
| 2026-04-06 | 7.90 |
| 2026-04-02 | 7.52 |
| 2026-04-01 | 7.83 |
| 2026-03-31 | 7.94 |
| 2026-03-30 | 7.88 |
| 2026-03-27 | 7.78 |
| 2026-03-26 | 7.98 |
| 2026-03-25 | 7.84 |
| 2026-03-24 | 8.06 |
| 2026-03-23 | 8.18 |
| 2026-03-20 | 8.09 |
| 2026-03-19 | 8.18 |
| 2026-03-18 | 7.64 |
| 2026-03-17 | 7.68 |
| 2026-03-16 | 7.76 |
| 2026-03-13 | 6.86 |
| 2026-03-12 | 6.99 |
| 2026-03-11 | 7.08 |
| 2026-03-10 | 7.30 |
| 2026-03-09 | 7.19 |
| 2026-03-06 | 7.07 |
| 2026-03-05 | 7.09 |
| 2026-03-04 | 7.15 |
| 2026-03-03 | 7.25 |
| 2026-03-02 | 7.20 |
| 2026-02-27 | 7.30 |
